基于症状、临床和常规生物学数据可将干燥病分层,其支持不同的病理生理通路
在395例干燥病患者的前瞻性队列中,三个聚类表现出不同的干扰素特征及T、B细胞活化标志物表达。BALS聚类中高干扰素特征与新增免疫抑制剂治疗风险相关(HR 9.38,95%CI 1.22-72.16),所有淋巴瘤均发生于高干扰素特征患者。
要点
- BALS和HSA聚类中CXCL13、IL-7、TNF-RII水平高于LSAHS聚类。
- 高干扰素特征主要见于BALS聚类(57%),HSA和LSAHS分别为48%和38%。
- BALS聚类中高干扰素特征与新增免疫抑制剂治疗风险相关(HR 9.38,95%CI 1.22-72.16)。
核心结论
- 三个干燥病聚类显示出不同的干扰素特征及T、B细胞活化标志物表达,证实存在不同的病理生理机制。
- 高干扰素特征可预测BALS聚类的系统性演变。
研究设计与样本
- 评估干燥综合征系统征象与演变队列是一项为期20年的前瞻性队列研究。
- 共纳入395例干燥病患者,94%为女性,中位年龄53岁(四分位距43-63岁)。
- 比较了IFN-α2、IFN-γ、CXCL10、CXCL13、BAFF、IL-7、fms样酪氨酸激酶3配体、CCL19和TNF-RII等生物标志物,并通过转录组分析评估干扰素特征。
- 根据三个聚类中的干扰素特征,比较了系统性和症状性演变、新增免疫抑制剂处方的风险及淋巴瘤风险。
主要发现
- BALS和HSA聚类中CXCL13、IL-7和TNF-RII水平高于LSAHS聚类。
- 高干扰素特征主要见于BALS聚类(57%),HSA聚类为48%,LSAHS聚类为38%。
- 该干扰素特征主要由I型干扰素驱动,IFN-α2水平较高。
- BALS聚类中,高干扰素特征与新增免疫抑制剂治疗风险较高相关(HR 9.38;95%CI 1.22-72.16)。
- 所有淋巴瘤均发生于高干扰素特征患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recently, three distinct phenotypes of patients with Sjögren disease (SjD) have been described based on cluster analysis: B cell active with low symptoms (BALS), high systemic activity (HSA), and low systemic activity with high symptoms (LSAHS). We aimed to assess whether these clusters were associated with distinct biomarkers and the prognostic value of interferon (IFN) signature. METHODS: The Assessment of Systemic Signs and Evolution in Sjögren's Syndrome cohort is a 20-year prospective cohort of patients with SjD. The following biomarkers were compared: IFN-α2, IFN-γ, CXCL10, CXCL13, BAFF, interleukin (IL)-7, fms-like tyrosine kinase 3 ligand, CCL19, and tumor necrosis factor receptor 2 (TNF-RII). IFN signature was assessed using transcriptomic analysis. We then compared systemic and symptomatic evolution, and the risk of new immunosuppressant prescription and of lymphoma, according to the IFN signature across the three clusters. RESULTS: A total of 395 patients (94% female, median age 53 [interquartile range 43-63] years) were included. Higher levels of CXCL13, IL-7, and TNF-RII were found in the BALS and HSA clusters compared with the LSAHS cluster. A high IFN signature was mainly found in the BALS cluster (57%, vs 48% and 38% in the HSA and LSAHS clusters, respectively). This IFN signature was mainly driven by type I IFN, with higher levels of IFN-α2. In the BALS cluster, a high IFN signature was associated with a higher risk of new immunosuppressant treatment (hazard ratio 9.38; 95% confidence interval 1.22-72.16). All lymphoma occurred in patients with high IFN signature. CONCLUSION: The three SjD clusters displayed distinct expressions of IFN signature and markers of T and B cell activation, confirming distinct pathophysiologic mechanisms. High IFN signature could predict systemic evolution in the BALS cluster.
引用
- Nguyen Y, Beydon M, Gottenberg JE, et al. Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data. Arthritis Rheumatol. 2025. PMID: 39721742. doi:10.1002/art.43096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。